|
Three AAPS Workshops will be held consecutively in the 2006 Spring Workshop Series, bringing together more than 700 pharmaceutical scientists to discuss and evaluate current issues affecting the field.
AAPS/FDA Third Bioanalytical Workshop: Quantitative Bioanalytical Methods Validation and Implementation – Best Practices for Chromatographic and Ligand Binding Assays
The quality of chromatographic and ligand binding assays is directly related to the quality of the underlying bioanalytical data. Through speeches, discussion panels and breakout sessions, leaders from the U.S. Food and Drug Administration (FDA) and pharmaceutical companies will review, evaluate and identify common practices, problems, existing guidance, white papers, and articles on bioanalysis for all types of molecules.
AAPS Workshop on Ensuring the Supply of Qualified Pharmaceutical Scientist Specialists in Product Development and Related Technologies that Meet Current and Future Needs
According to industry executives interviewed in an AAPS survey, graduate programs in colleges of pharmacy are increasingly failing to produce sufficient numbers of appropriately qualified specialists in product development and related pharmaceutical technologies. Chaired by Dr. Larry Augsburger of the University of Maryland School of Pharmacy, this meeting will utilize plenary breakout sessions to identify creative solutions and the steps needed to achieve these solutions. Speakers include Drs. Ajaz Hussain of Sandoz, Kenneth Miller of the American Association of Colleges of Pharmacy, and Alice Till of PhRMA.
AAPS Workshop on Dissolution Testing for the 21st Century: Linking Critical Quality Attributes and Critical Process Parameters to Clinically Relevant Dissolution Method/Specification
Scientists rely on the dissolution characteristics of their solid dosage form for information on the performance of the formulation. Dissolution testing can play a key role in identifying the critical process parameters that have a direct effect on the quality of the drug product. Speakers from U.S. Pharmacopeia, the U.S. FDA and pharmaceutical companies will highlight traditional dissolution testing and its relevance, to real time monitoring of critical quality attributes (CQA). This session will also shed light into the technology that could be used to predict real time release rate of dosage forms.
| 